#1 Clinical Trials Search in Europe

Study on the Safety and Effects of Zanidatamab, Palbociclib, and Fulvestrant for Patients with Advanced or Metastatic HER2-Positive, HR-Positive Breast Cancer

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of breast cancer known as HER2-positive, HR-positive breast cancer. This type of cancer is characterized by the presence of certain proteins and hormone receptors that can promote the growth of cancer cells. The study involves a combination of treatments to evaluate their safety and how well they are tolerated by patients. The treatments being studied include a new medication called JZP598, which contains the active substance zanidatamab, and two other medications, palbociclib and fulvestrant. These medications are used together to see if they can effectively manage the disease.

The purpose of the study is to find a suitable dose of JZP598 when used with palbociclib and fulvestrant and to assess the combination’s ability to control the cancer. The study is divided into two parts. In the first part, researchers will determine the best dose of JZP598 to use with the other medications. In the second part, they will evaluate how well this combination works in treating the cancer. Participants will receive the medications through different methods: JZP598 is given as an infusion, palbociclib is taken orally as a capsule, and fulvestrant is administered as an injection.

Throughout the study, participants will be monitored for any side effects and how their cancer responds to the treatment. The study aims to provide valuable information on the effectiveness and safety of using these medications together for treating HER2-positive, HR-positive breast cancer. The trial is expected to continue until early 2026, with the goal of improving treatment options for patients with this type of breast cancer.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and current health status.

A new or archived tumor sample is required for central review to confirm HER2-positive and HR-positive status.

2 treatment initiation

The treatment phase begins with the administration of zanidatamab (JZP598) via intravenous infusion. The dosage is determined based on the initial assessment.

Alongside zanidatamab, fulvestrant (Faslodex 250 mg) is administered through intramuscular injection.

Additionally, palbociclib (IBRANCE 125 mg) is taken orally in the form of hard capsules.

3 ongoing treatment

The treatment continues with regular administration of the medications. Zanidatamab is given intravenously, fulvestrant intramuscularly, and palbociclib orally.

The frequency and dosage of each medication are adjusted based on individual response and tolerance.

4 monitoring and evaluation

Regular monitoring is conducted to evaluate the safety and effectiveness of the treatment. This includes checking for any side effects or adverse reactions.

Blood tests and imaging studies may be performed to assess the response to treatment and adjust the regimen as necessary.

5 completion of treatment

The treatment phase concludes as per the study protocol or if the patient experiences significant improvement or adverse effects.

A final assessment is conducted to evaluate the overall response to the treatment and to plan any necessary follow-up care.

Who Can Join the Study?

  • Must have a confirmed diagnosis of breast cancer that is either locally advanced (cannot be removed by surgery) or has spread to other parts of the body. The cancer must be HER2-positive and HR-positive. HER2-positive means the cancer has high levels of a protein called HER2, and HR-positive means the cancer grows in response to hormones like estrogen or progesterone.
  • Must be able to provide a new or recent tumor sample for testing to confirm HER2 status.
  • Must have received previous treatments with specific cancer drugs: trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1). If these treatments were not received due to lack of access or medical reasons, eligibility may still be possible after discussion with the study team.
  • Must have areas of cancer that can be measured or evaluated according to specific criteria.
  • Must be 18 years of age or older.
  • Must have a good general health status, as measured by a score of 0 or 1 on a specific scale used by doctors.
  • Must have a life expectancy of at least 3 months, as judged by the study doctor.
  • Must have certain levels of blood cells and liver and kidney function within specific ranges, as determined by blood tests.
  • Must have a healthy heart function, as shown by a test called LVEF (left ventricular ejection fraction).
  • Any side effects from previous cancer treatments must have improved to a mild level, except for hair loss or mild nerve damage.
  • If female and able to have children, must have a negative pregnancy test before starting the study.
  • If able to have children, must agree to use two reliable methods of birth control during the study and for 12 months after the last dose of study medication.
  • Female participants must agree not to breastfeed or donate eggs during the study and for 12 months after the last dose of study medication.
  • Male participants must agree not to donate sperm during the study and for 12 months after the last dose of study medication.
  • Must sign a consent form agreeing to participate in the study and understand what it involves.

Who Cannot Join the Study?

  • Patients who do not have breast cancer that is locally advanced (meaning it has spread to nearby areas but not to distant parts of the body) or metastatic (meaning it has spread to distant parts of the body).
  • Patients whose breast cancer is not HER2-positive. HER2 is a protein that can promote the growth of cancer cells. In some cancers, high levels of HER2 are present.
  • Patients whose breast cancer is not HR-positive. HR stands for hormone receptor, and HR-positive means the cancer cells grow in response to hormones like estrogen or progesterone.
  • Patients who are not within the specified age range for the study.
  • Patients who are not part of the specified clinical trial groups.
  • Patients who are considered part of a vulnerable population, which may include individuals who are unable to give informed consent or are at higher risk of harm.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Hospital Universitario Virgen De La Victoria Malaga Spain
Hokgrvhj Vqor dettoyll Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not recruiting
03.06.2020

Trial locations

Investigated drugs:

ZW25 is an investigational medication being studied for its potential to treat certain types of breast cancer. It is being tested in combination with other medications to determine the best dose and to evaluate its safety and effectiveness in patients with advanced or metastatic breast cancer that is positive for HER2 and hormone receptors.

Palbociclib is a medication used to treat certain types of breast cancer. It works by inhibiting proteins that are involved in cell division, which can help slow down or stop the growth of cancer cells. In this trial, it is being used in combination with other treatments to assess its effectiveness in patients with advanced breast cancer.

Fulvestrant is a medication used to treat hormone receptor-positive breast cancer. It works by blocking the effects of estrogen in the body, which can help slow the growth of cancer cells that rely on this hormone. In this study, it is being combined with other medications to evaluate its role in treating advanced breast cancer.

Investigated diseases:

Breast Cancer – Breast cancer is a disease where cells in the breast grow uncontrollably. It can begin in different parts of the breast, most commonly in the ducts or lobules. The disease can be classified based on the presence of certain receptors, such as hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2). In cases where the cancer is HER2-positive and HR-positive, it means the cancer cells have more HER2 proteins and hormone receptors than normal cells. This type of breast cancer can be locally advanced, meaning it has spread to nearby tissues, or metastatic, meaning it has spread to other parts of the body. The progression of the disease can vary, with some cases growing slowly and others more rapidly.

Trial ID:
2023-508135-30-00
Protocol code:
ZWI-ZW25-202
NCT ID:
NCT04224272
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Italy Spain

  • Study of melphalan followed by eribulin, vinorelbine, or capecitabine versus eribulin, vinorelbine, or capecitabine alone for metastatic breast cancer patients with liver disease

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain